Clinical Decision Support software companies raised $661 million in 15 venture capital (VC) funding rounds in Q1 2021, compared to $505 million in 12 funding rounds in Q4 2020, a 31% increase in quarter-over-quarter funding activity, according to the latest Mercom Digital Health Funding and M&A Report.
Strive Health, a kidney care decision-making platform, secured a $140 million Series B round of funding led by CapitalG, Alphabet’s independent growth fund. Redpoint, New Enterprise Associates (NEA), Town Hall Ventures, Ascension Ventures, and Echo Ventures also participated in the funding round. Including the latest funding round, Strive Health has raised $223.5 million to date.
Paige, a New York-based provider of computational pathology for diagnosing and treating cancer, raised $100 million in a Series C financing round. The company, founded in 2018, has raised over $195 million to date, including a $15 million Series B funding in 2020 from Goldman Sachs Merchant Banking Division.
Syapse, a precision medicine platform that supports precision oncology care and drug discovery, announced the closing of a $68 million growth equity investment round. The round was led by Ally Bridge Group (ABG), with participation from Northpond Ventures and existing investors.
Ibex Medical Analytics, which develops AI-powered clinical-grade solutions that help pathologists detect and grade cancer in biopsies, announced a $38 million Series B financing round. Octopus Ventures and 83North led the funding round with additional participation from aMoon, Planven Entrepreneur Ventures, and Dell Technologies Capital, the corporate venture arm of Dell Technologies. Including the latest funding round, Ibex has raised $52 million to date.
Volta Medical, which develops AI software solutions to assist cardiac electrophysiologists in the operating room, raised $28 million in financing. Gilde Healthcare led the round with participation from existing shareholder Pasteur Mutualité. According to the company, its software also assists cardiologists in the real-time identification of specific abnormal electrograms, known as dispersed electrograms.